10/09/2015 - 10:32am

The New York Times outlines the controversy surrounding the recent FDA approval of Oxycontin in children. “Just because OxyContin has been abused or prescribed inappropriately doesn’t mean we should deprive the children who need the drug,” Kathleen Neville, pediatric oncologist at Arkansas Children's Hospital told The New York Times, adding it is “our obligation to have the best level of evidence for its use in children.” (The New York Times)


10/08/2015 - 10:00am

More than 80% of Americans support medical school and physician residency programs to provide training for physicians in how to treat chronic pain and how to detect and treat addiction to prescription pain medication. 

10/07/2015 - 11:51am

Approximately 4 in 5 U.S. adults in their 40s (80%) and 50s (83%) reported concern around the security of their health data. 

10/07/2015 - 11:20am

Camber Pharmaceuticals has rolled out its generic version of Mirapex and Plavix.

10/07/2015 - 10:32am

More than 260,000 pharmacists have been trained to provide immunization services through APhA, association says. 

10/05/2015 - 11:43am

The Generic Pharceutical Association’s CEO and President Chip Davis offered his recommendations for the Trans-Pacific Partnership. 

10/05/2015 - 11:40am

The New York Times outlines the impact price increases of Valeant Pharmaceutical's Cuprimine has on one family, juxtaposing Valeant's pharmaceutical business model against the threat of government action. “Cuprimine is just one of many Valeant drugs whose prices have spiked as part of the company’s concerted strategy, which has richly rewarded its investors and made it one of Wall Street’s most popular health stocks,” the article said. “But Valeant’s habit of buying up existing drugs and raising prices aggressively, rather than trying to develop new drugs, has also drawn the ire of lawmakers and helped stoke public outrage against the growing trend of higher and higher drug prices imposed by big drug companies.” (New York Times)



10/05/2015 - 11:22am

Overall, 22% of consumers who are enabling their health management through technology in 2015 vs. 13% two years ago.

10/01/2015 - 2:40pm

Tussionex has launched its generic of Tussionex, taking over marketing and distribution from Par Pharmaceuticals after Par's rights to the drug expire.